IBI-354

IBI-354 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IBI-354, covering 2026-02-25 to 2026-02-25. Get the full timeline:

Most recent: Clinical Trial Update: IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer [Phase 3]

See pricing